The negative polls come as the Congressional Budget Office estimates the bill would lead to 23 million more uninsured people. » Read More
Blue Cross and Blue Shield NC says it would have asked for just an 8.8 percent increase, and not almost 24 percent. » Read More
The Republican Obamacare replacement bill includes provisions that could allow insurers to eliminate essential health benefits in plans. » Read More
By: Bertha Coombs
UnitedHealth Group's Optum unit has signed a multiyear agreement with Merck to develop a better way to reimburse drugmakers. » Read More
Valeant Pharmaceuticals on Wednesday named Howard Schiller interim chief executive officer, effective immediately.
There hasn't been a significant increase in part-time jobs due to the Affordable Care Act.
Lumosity claimed its brain games could improve mental performance and stave off age-related cognitive decline.
Chipotle warned investors in a filing Wednesday that its comparable-restaurant sales nosedived 14.6 percent in the fourth quarter.
Martin Shkreli was accused by an ex-employee of contacting the man's family repeatedly during a lawsuit.
Want to stay healthy? These are the top 11 apps prescribed by doctors in the Ochsner Health System.
Here are how some food-related stocks are moving on news of an avian flu outbreak in Iowa.
The sheer volume and pace of biotech offerings are causing some to question whether the sector is nearing the end of its years of buoyancy.
Executives at J.P. Morgan's healthcare conference discuss the technologies they believe with change medicine as we know it.
Biopharma executives at the J.P. Morgan Healthcare Conference talk about this year's biggest challenges.
Ariad CEO Harvey Berger, tells CNBC's Meg Tirrell commercially the company had a good year and provides insight into its new cancer drug, Iclusig.
Vertex CEO Dr. Jeffrey Leiden tells CNBC's Meg Tirrell about the company's new drug trials and focus areas in 2015.
Mike Narachi, Orexigen CEO, speaks with CNBC's Meg Tirrell about its obesity drug and program.
Hans Bishop, Juno Therapeutics co-founder and CEO, discusses promising data for new cancer immunotherapy approaches.
David Cordani, Cigna president & CEO, weighs in on rival Aetna's wage plan and explains Cigna's growth strategy.
Michelle Berrey, Chimerix CEO, discusses the testing of its Ebola drug Brincidofovir in a clinical setting in West Africa, with CNBC's Meg Tirrell.
Valeant CEO Mike Pearson tells CNBC's Meg Tirrell the company is on a mission to prove allegations against the business model are not true. Pearson says Valeant is unlikely to work with Bill Ackman.
Sam Waksal, former Imclone Systems CEO, reveals how the ImClone scandal has impacted his life.
Alex Gorsky, Johnson & Johnson chairman and CEO, discusses how the ACA and the recovery in the economy is impacting business.
Flemming Ornskov, Shire CEO, tells CNBC's Meg TIrrell it is the right time for the proposed acquisition of NPS Pharmaceuticals.
Get the best of CNBC in your inbox